IZIlham Zarguan

Ilham Zarguan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilham Zarguan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Abdelaziz Benjouad

    Center for Research on Health Sciences (CReSS), International Faculty of Medicine, College of Health Sciences, International University of Rabat, Technopolis Parc, Rocade of Rabat-Salé, Sala-Al Jadida 11100, Morocco

    5 shared publications
  • Lamiae Belayachi

    International Faculty of Medicine, Health Sciences Research Center, College of Health Sciences, International University of Rabat, Technopolis Parc, Rocade of Rabat-Salé, Sala-Al Jadida 11100, Morocco

    5 shared publications
  • Devan Buchanan

    Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA

    2 shared publications
  • Hanane Abbou

    Mohammed VI University of Sciences and Health (UM6SS), Casablanca, Morocco

    2 shared publications
  • Razana Zegrari

    Laboratory of Drug Sciences (LRSM), Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health (UM6SS), Casablanca 82403, Morocco

    2 shared publications
  • Rihab Festali

    Mohammed VI University of Sciences and Health Morocco‐UM6SS, Mohammed VI Faculty of Medicine – Casablanca; Research Laboratory of Microbiology Infectious Diseases Allergology and Pathogen surveillance (LARMIAS) Casablanca Morocco

    2 shared publications

Latest Publications

  • Open Access

    Evolution of Hsp90 targeting: From stress biology to clinical translation

    by Ilham Zarguan, Lamiae Belayachi, Abdelaziz Benjouad, Ahmed Chadli

  • Open Access

    Phytochemical Profiling and Structure-Based Computational Characterization of Marrubium vulgare L. Compounds as Hsp90 Modulators

    by Ilham Zarguan, Hanane Abbou, Razana Zegrari, Rihab Festali, Devan Buchanan, Abdelaziz Benjouad, Lamiae Belayachi

    Marrubium vulgare L. is a medicinal plant widely used in traditional medicine, with emerging evidence of anticancer potential. This study investigated its bioactive compounds as inhibitors of Heat Shock Protein 90 alpha (Hsp90α), a molecular chaperone essential for oncogenic protein stability. Organic and aqueous extracts were profiled using high-performance liquid chromatography–mass spectrometry (HPLC–MS), revealing a diverse phytochemical composition. Identified compounds were screened against the full-length crystal structure of Hsp90α using a structure-based computational workflow that included extra-precision and domain-specific molecular docking, molecular dynamics (MD) simulations, and MM/GBSA binding free energy calculations. Pharmacokinetic and toxicity profiles were evaluated through ADMET predictions. This study elucidated the chemical composition of the plant and identified two hit compounds: Forsythoside B bound preferentially to the middle domain, potentially interfering with client protein interactions, and chlorogenic acid targeted the C-terminal domain, which regulates dimerization and allosteric activity. Both ligands displayed stable protein–ligand interactions during MD and favorable ADMET properties. These findings provide the first integrated chemical and computational prediction framework, suggesting that some M. vulgare metabolites may interact with Hsp90, highlighting its potential as a source of novel anticancer scaffolds and laying the groundwork for experimental validation and drug development.


  • Open Access

    Phytochemical Profiling and Structure-Based Computational Characterization of Marrubium Vulgare L. Compounds as Hsp90 Modulators

    by Ilham Zarguan, Hanane Abbou, Razana Zegrari, Rihab Festali, Devan Buchanan, Abdelaziz Benjouad, Lamiae Belayachi

    Marrubium vulgare L. is a medicinal plant widely used in traditional medicine, with emerging evidence of anticancer potential. This study investigated its bioactive com-pounds as inhibitors of Heat Shock Protein 90 alpha (Hsp90α), a molecular chaperone essential for oncogenic protein stability. Organic and aqueous extracts were profiled using high-performance liquid chromatography–mass spectrometry (HPLC–MS), re-vealing a diverse phytochemical composition. Identified compounds were screened against the full-length crystal structure of Hsp90α using a structure-based computa-tional workflow that included extra-precision and domain-specific molecular docking, molecular dynamics (MD) simulations, and MM/GBSA binding free energy calculations. Pharmacokinetic and toxicity profiles were evaluated through ADMET predictions. This study elucidated the chemical composition of the plant and identified two hit com-pounds: Forsythoside B bound preferentially to the middle domain, potentially inter-fering with client protein interactions, and chlorogenic acid targeted the C-terminal domain, which regulates dimerization and allosteric activity. Both ligands displayed stable protein–ligand interactions during MD and favorable ADMET properties. These findings provide the first integrated chemical and computational analysis of M. vulgare targeting Hsp90α, highlighting its potential as a source of novel anticancer scaffolds and laying the groundwork for experimental validation and drug development.


  • Open Access

    Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review

    by Ilham Zarguan, Sonia Ghoul, Lamiae Belayachi, Abdelaziz Benjouad

    Breast cancer, the most invasive cancer in women globally, necessitates novel treatments due to prevailing limitations of therapeutics. Search of news anticancer targets is more necessary than ever to tackle this pathology. Heat-Shock Protein 90 (HSP90), a chaperone protein, is implicated in breast cancer pathogenesis, rendering it an appealing target. Looking for alternative approach such as Plant-based compounds and natural HSP90 inhibitors offer promising prospects for innovative therapeutic strategies. This study aims to identify plant-based compounds with anticancer effects on breast cancer models and elucidate their mechanism of action in inhibiting the HSP90 protein. A systematic review was conducted and completed in January 2024 and included in vitro, in vivo, and in silico studies that investigated the effectiveness of plant-based HSP90 inhibitors tested on breast cancer models. Eleven studies were included in the review. Six plants and 24 compounds from six different classes were identified and proved to be effective against HSP90 in breast cancer models. The studied plant extracts showed a dose- and time-dependent decrease in cell viability. Variable IC50 values showed antiproliferative effects, with the plant Tubocapsicum anomalum demonstrating the lowest value. Withanolides was the most studied class. Fennel, Trianthema portulacastrum, and Spatholobus suberectus extracts were shown to inhibit tumor growth and angiogenesis and modulate HSP90 expression as well as its cochaperone interactions in breast cancer mouse models. The identified plant extracts and compounds were proven effective against HSP90 in breast cancer models, and this inhibition showed promising effects on breast cancer biology. Collectively, these results urge the need of further studies to better understand the mechanism of action of HSP90 inhibitors using comparable methods for preclinical observations.


  • Open Access

    Comment on Budryn et al. Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies. Nutrients 2022, 14, 2476

    by Ilham Zarguan, Abdelaziz Benjouad, Lamiae Belayachi

    It is with great interest that we read the article entitled “Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies” published in Nutrients 2022, 14, 2476